U.S. markets open in 5 minutes

  • S&P Futures

    4,173.75
    +20.25 (+0.49%)
     

  • Dow Futures

    33,409.00
    +254.00 (+0.77%)
     

  • Nasdaq Futures

    14,066.75
    +31.75 (+0.23%)
     

  • Russell 2000 Futures

    2,252.50
    +21.90 (+0.98%)
     

  • Crude Oil

    71.49
    -0.15 (-0.21%)
     

  • Gold

    1,776.80
    +7.80 (+0.44%)
     

  • Silver

    25.99
    +0.02 (+0.06%)
     

  • EUR/USD

    1.1908
    +0.0042 (+0.36%)
     

  • 10-Yr Bond

    1.4700
    +0.0200 (+1.38%)
     

  • Vix

    20.06
    +2.31 (+13.01%)
     

  • GBP/USD

    1.3893
    +0.0084 (+0.61%)
     

  • USD/JPY

    110.1600
    +0.0100 (+0.01%)
     

  • BTC-USD

    32,477.73
    -1,427.45 (-4.21%)
     

  • CMC Crypto 200

    792.82
    -147.13 (-15.65%)
     

  • FTSE 100

    7,022.80
    +5.33 (+0.08%)
     

  • Nikkei 225

    28,010.93
    -953.15 (-3.29%)
     

Global Acute Lymphoblastic Leukemia (ALL) Clinical Landscape Market Report 2021-2027

·4 min read

DUBLIN, June 21, 2021 /PRNewswire/ -- The "Market Spotlight: Acute Lymphoblastic Leukemia (ALL)" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo
Research and Markets Logo

This Market Spotlight report covers the Acute Lymphoblastic Leukemia (ALL) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

The report estimates that in 2018, there were 86,600 incident cases of acute lymphoblastic leukemia (ALL) worldwide, and expects that number to increase to 93,500 incident cases by 2027.

Approved drugs in the ALL space focus on a wide variety of targets. The majority of these therapies are administered via the intravenous route, with the remaining products being available in oral and intramuscular formulations.

The highest proportion of industry-sponsored drugs in active clinical development for ALL are in Phase I, with only one drug in the NDA/BLA phase.

Therapies in development for ALL focus on a wide variety of targets. The majority of pipeline drugs in development are administered via the intravenous route, with the remainder being oral and intramuscular formulations.

High-impact upcoming events for drugs in the ALL space comprise topline Phase II trial results for Sarclisa, and an expected supplemental BLA filing for Tecartus.

The overall likelihood of approval of a Phase I hematologic asset is 8.7%, and the average probability a drug advances from Phase III is 58.9%. Drugs, on average, take 9.4 years from Phase I to approval, compared to 9.6 years in the overall oncology space.

The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for ALL have been in the early and midphases of development, with 92% of trials in Phase I-II, and only 8% in Phase III-IV.

The US has a substantial lead in the number of ALL clinical trials globally. France leads the major European markets, while China has the top spot in Asia.

Novartis has the highest number of completed clinical trials for ALL, with 47 trials.

Novartis also leads industry sponsors with the highest overall number of clinical trials for ALL

Key Topics Covered:

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Definition

  • Patient segmentation

  • Symptoms

  • Risk factors

  • Diagnosis

TREATMENT

  • Chemotherapy

  • Corticosteroids

  • TKI therapy

  • Immunotherapy

  • Radiation therapy

  • Stem cell transplant

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • Blincyto for ALL (December 10, 2019)

  • GC022 for ALL (December 7, 2019)

  • Blincyto for ALL (September 24, 2019)

KEY UPCOMING EVENTS

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • ADC Therapeutics In Asia JV, License Deal With Overland

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status

  • Sponsors by phase

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES
Figure 1: Trends in incident cases of ALL, 2018-27
Figure 2: Overview of pipeline drugs for ALL in the US
Figure 3: Pipeline drugs for ALL, by company
Figure 4: Pipeline drugs for ALL, by drug type
Figure 5: Pipeline drugs for ALL, by classification
Figure 6: Blincyto for ALL (September 24, 2019): Phase III - Pediatric (1st Relapse)
Figure 7: Key upcoming events in ALL
Figure 8: Probability of success in the hematologic pipeline
Figure 9: Clinical trials in ALL
Figure 10: Top 10 drugs for clinical trials in ALL
Figure 11: Top 10 companies for clinical trials in ALL
Figure 12: Trial locations in ALL
Figure 13: ALL trials status
Figure 14: ALL trials sponsors, by phase

LIST OF TABLES
Table 1: Incident cases of ALL, 2018-27
Table 2: Marketed drugs for ALL
Table 3: Pipeline drugs for ALL in the US
Table 4: Blincyto for ALL (December 10, 2019)
Table 5: GC022 for ALL (December 7, 2019)
Table 6: Blincyto for ALL (September 24, 2019)
Table 7: Historical global sales, by drug ($m), 2015-19
Table 8: Forecasted global sales, by drug ($m), 2021-25


Companies Mentioned

  • Fate Therapeutics

  • Novartis

  • Ono Pharmaceutical

For more information about this report visit https://www.researchandmarkets.com/r/2xfnfk

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision
Cision

View original content:http://www.prnewswire.com/news-releases/global-acute-lymphoblastic-leukemia-all-clinical-landscape-market-report-2021-2027-301316239.html

SOURCE Research and Markets

Recommended Stories

  • Bitcoin Leads in $1 Billion 24-Hour Liquidation Pile-Up

    Bitcoin (BTC) heads up a huge liquidations pile-up as recorded on Bybt. At the time of press, the trading information platform recorded well over $1 billion liquidated in 24 hours across exchanges.

  • Vir, GSK say new data confirms their COVID-19 treatment can reduce hospitalization and death

    Shares of Vir Biotechnology Inc. gained 1.4% in premarket trading on Monday after the company said the COVID-19 antibody treatment it developed with GlaxoSmithKline cut the risk of hospitalization and death among adults at high risk. The confirmatory data came from a Phase 3 clinical trial that was used to inform the emergency-use authorization granted last month to sotrovimab, the companies' COVID-19 monoclonal antibody treatment. Vir also said the National Institutes of Health updated its guid

  • QuestEx Receives Multi-Year Permit for Drilling on the Sofia Property and Commences Exploration Program

    QuestEx Gold & Copper Ltd. (TSXV: QEX) ("QuestEx" or the "Company") is pleased to announce that the British Columbia ("BC") Ministry of Mines has issued a multi-year area-based permit that will allow QuestEx to begin a fully funded drill program at its 91 square kilometre ("km") 100% owned Sofia property in BC's prolific Toodoggone mining district.

  • We have $1.6 million but most is locked in our 401(k) plans — how can we retire early without paying so much in taxes?

    You bring up an interesting dilemma some retirement savers may not think of, which is having your retirement assets locked away in investment portfolios intended to be used at an older age. Employer-sponsored retirement accounts, such as 401(k) plans, are a great tool for investing for retirement because they are tax-deferred, which means more money is growing until it’s time to withdraw. The first task is to double check on your company’s policy for the age 55 rule (for readers unfamiliar with this rule, it allows people age 55 or older who were separated from their jobs — either because they were fired or voluntarily left — to tap into the 401(k) from their current employer before the required age 59 ½).

  • Iran stores more oil on tankers as it counts days to enter markets

    Iran could quickly export millions of barrels of oil it is holding in storage if it reaches a deal with the United States on its nuclear programme and has been moving oil into place to prepare for an eventual restart, four traders and industrial sources said. The U.S. and Iran began in mid-June their sixth round of indirect talks on reviving a 2015 nuclear deal that former U.S. President Donald Trump pulled out of in 2018. Trump reimposed sanctions on Iran’s energy sector, leading refiners in many countries to shun Iranian crude and forcing Tehran to pump well below capacity.

  • Significant Discovery Reveals New Antiviral Properties of Tetra Bio-Pharma's Innovative Drug ARDS-003

    Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development announced today that its investigational new drug ARDS-003 has been studied in a viral infected organoid model as part of a research collaboration between Targeted Pharmaceuticals ("Targeted") and George Mason University. ARDS-003 is a new patent protected therapeutic developed to treat hyperinflammatory conditions, such as those seen in patients

  • Supply Chain Bottlenecks Drive Factory Decisions at This Maker of Boats, Motorcycles, ATVs

    Sports-vehicle maker Polaris is changing its manufacturing and sales strategies on the fly to meet strong demand while coping with shortages of materials and parts.

  • Prices of GPUs Fall, Supply Increases as China Cracks Down on Crypto Mining

    Computer hardware sites are beginning to see GPU stocks resume back to pre-pandemic levels while prices have dropped between 5-10%.

  • IBM Canada Announces New Office in Downtown Toronto

    IBM Canada (NYSE: IBM) today announced it would be merging four Toronto-based offices into a single flexible workspace to be located at 16 York in Toronto's downtown core. The new office will include an AI and hybrid cloud client showcase centre, collaboration spaces for use by both employees and clients, and space for IBM Garage, a globally recognized design approach to innovation and digital transformation.

  • GSK to boost spending power of pharma business post break-up

    GlaxoSmithKline will lay out plans to boost the spending power of its research-focused pharmaceuticals business at an investor day on Wednesday, as analysts call on the British drugmaker to boost drug development prospects with takeovers or alliances. New GSK, the pharma business to be separated from its consumer product operations next year, will cut dividend payouts and shift some debt to the consumer unit, leaving scope for investments to revive its sluggish stock market performance. Luke Miels, chief commercial officer at GSK, told Reuters that the market was underestimating the company's value "both in terms of our growth prospects with the products that we have in the market now, and also our (drug development) pipeline".

  • ‘I am so relieved’: People covered by Obamacare react to Supreme Court decision

    Laurie Rozgonyi says she doesn’t have a lot of good luck. Despite no family history of cervical cancer, Rozgonyi developed it years ago. With that frame of mind, Rozgonyi was bracing for the U.S. Supreme Court to undo the Affordable Care Act “because I don’t have a good track record with good luck.”

  • China's Cryptocurrency Mining Crackdown Intensifies, Spreads To Sichuan

    Keeping a tough stance on cryptocurrencies, China has issued an order to crack down on crypto mining operations in Sichuan’s southwest province, Reuters reported. What Happened: On Friday, the Sichuan branch of the National Development and Reform Commission (NDRC) and the Sichuan Energy Bureau ordered cryptocurrency mining projects closed in the major mining center. The Commission demanded the closure of 26 suspected cryptocurrency mining projects by Sunday in the province. The authorities have

  • Amazon, Apple most valuable brands but China's rising - Kantar survey

    Amazon and Apple are the world's most valuable brands but Chinese brands are rising up the leaders list and are more valuable than Europe's top brands, according to a global ranking by Kantar’s BrandZ. Amazon, founded in 1994 by Jeff Bezos, remained the world's most valuable brand with an estimated value of $684 billion, followed by Apple, founded in 1976, at $612 billion and Google at $458 billion, Kantar said. Tencent, China's biggest social media and video games company, was the People's Republic's top brand, in fifth place, while Alibaba was in seventh place.

  • How Do I Roll Over a SIMPLE IRA to a Roth IRA?

    Here's how to convert your SIMPLE IRA to a Roth IRA via rollover after you leave your job; you can also convert to a Roth if you are still active in the plan.

  • SoftBank, Nomura Tapped to Offer Moderna Shots for Employees

    (Bloomberg) -- In a country where workplaces play an outsized role in people’s lives, Japan is betting that enlisting its largest corporations to roll out Covid-19 vaccines will add fuel to a much-scrutinized inoculation drive.Still grappling with a rollout that’s deployed only enough doses to cover 11% of the population, the Japanese government is allowing its biggest corporate brand names and employers like Toyota Motor Corp., SoftBank Group Corp., and Nomura Holdings Inc. to administer shots

  • U.S. Plans to Spend Big on Critical Minerals; Choosing Where Isn’t Easy

    As the U.S. and its allies chase China in procuring critical minerals essential for modern technologies, they face a major hurdle: a lack of companies and projects with an established record.

  • Norwegian Air fires CEO in 'surprise' move after restructuring

    OSLO (Reuters) -Norwegian Air has sacked Chief Executive Jacob Schram who led the budget carrier through restructuring and said it was promoting Chief Financial Officer Geir Karlsen to the top job with immediate effect. The board voted on June 20 to end Schram's 18-month tenure but the airline said he would support the carrier on a full-time basis during his notice period up to March 31. "The board's decision to fire me came as a big surprise," Schram told Reuters.

  • Oil Price Fundamental Weekly Forecast – Traders Eyeing US Dollar, Potential US-Iran Deal;

    This week, traders could be surprise by the announcement of a nuclear deal between the US and Iran.

  • How Capital Gains Tax Works on Pension Funds

    Pension funds are a type of plan where employers, employees, or a combination of both pay into a fund to provide retirement benefits to employees. This pension money is invested in a variety of financial securities over many years. Pension funds build up assets over time and provide individual employees with benefits after they retire.

  • China Faces Flareups in Its Bid to Tame Commodities Boom

    (Bloomberg) -- Commodities are in retreat, but it’s too early for Beijing to declare victory in its two-month battle to quash prices and ease rising factory costs.China has rolled out a swathe of measures -- from trading curbs to releases from state stockpiles -- in a sweeping effort to stem inflation by cooling runaway commodities. Many of the prices have fallen from May peaks, with steel in particular beating a rapid retreat.But it’s unclear exactly how much credit for that lies with Beijing,